KIM Ha Young (KR),КИМ Ха Юнг (KR),KIM In Woo (KR),КИМ Ин Ву (KR),JUN Sun Ah (KR),ЮН Сун Ах (KR),NA Yun Soo (KR),НА Юн Су (KR),LEE Hyung Geun (KR),ЛИ Хюнг Гын (KR),CHO Min Jae (KR),ЧО Мин Джэ (KR),LEE,KIM Ha Young,КИМ Ха Юнг,KIM In Woo,КИМ Ин Ву,JUN Sun Ah,ЮН Сун Ах,NA Yun Soo,НА Юн Су,LEE Hyung Geun,ЛИ Хюнг Гын,CHO Min Jae,ЧО Мин Джэ,LEE Jun Hee,ЛИ Джун Хи,KIM Hyo Shin,КИМ Хё Син,YOON Yun soo,ЁО Ю
申请号：
RU2015113333
公开号：
RU0002645711C2
申请日:
2013.10.15
申请国别(地区):
RU
年份:
2018
代理人:
摘要：
FIELD: biochemistry.SUBSTANCE: invention relates to a compound represented by formula 1 or a pharmaceutically acceptable salt thereof, where R1 – aryl or heteroaryl selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, furanyl, isoxazolyl, pyrazolyl and thienyl, wherein aryl or heteroaryl is unsubstituted or substituted by one or two substituents independently selected from the group consisting of halogen, consisting of C1–4alkyl, C1–4haloalkyl and halogen； R2 – heteroaryl selected from the group consisting of furanyl, imidazolyl, isoxazolyl, pyrazolyl, pyridinyl, pyrimidinyl, thiazolyl and thienyl, wherein heteroaryl is unsubstituted or substituted with one or two substituents independently selected from the group consisting of halogen, consisting of C1–4alkyl, C3–6cycloalkyl, halogen, morpholino, piperazinyl, piperidinyl, pyridinyl and pyrrolidinyl； R3 – thiazolyl or thiadiazolyl； X1 – CH； X2 – N or X1 – N； X2 – CH； Y – O； Z – CR4, and R4 – H, halogen or CN； R5 – H or halogen. Invention also relates to a compound represented by formula 1, or a pharmaceutically acceptable salt thereof, where R1 – hydrogen, halogen or aryl or heteroaryl, selected from the group consisting of phenyl, pyridinyl and furanyl, wherein aryl or heteroaryl is unsubstituted or substituted by halogen； R2 – aryl or heteroaryl, selected from the group consisting of furanyl, phenyl, pyrazolyl and pyridinyl, where aryl or heteroaryl is unsubstituted or substituted by C1–4alkyl； R3 – thiazolyl； X1 – CH or N； X2 – CH or N with the proviso that at least one of X1 and X2 is CH； Y – CH(OH)； Z – CR4, where R4 is H or halogen； R5 – H. Invention relates to a pharmaceutical composition for preventing or treating a disease, associated with sodium channel blocker Nav1.7, and to relieve pain, associated with sodium channel blocker Nav1.7 containing a compound or a pharmaceutically acceptable salt thereof of formula (1) as an active ingredient and a pharmaceutically acceptable carrier, adjuvan
